AIM ImmunoTech logo
AIM ImmunoTech AIM
$ 0.86 -14.24%

Quarterly report 2025-Q3
added 11-17-2025

report update icon

AIM ImmunoTech Revenue 2011-2026 | AIM

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue AIM ImmunoTech

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
141 K 135 K 163 K 140 K 367 K 437 K 92 K 133 K 197 K 150 K 213 K 161 K

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
437 K 92 K 194 K

Quarterly Revenue AIM ImmunoTech

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
26 K 25 K 16 K - 35 K 50 K 40 K - 46 K 42 K 49 K - 21 K 30 K 33 K - 33 K 23 K 28 K - 36 K 40 K 45 K - 61 K 29 K - - 38 K 33 K 56 K - 90 K 213 K 84 K - 22 K 15 K 39 K - 23 K 47 K 36 K - 45 K 36 K 76 K 36 K 36 K 36 K 42 K 53 K 39 K 49 K 72 K 38 K 45 K 36 K 42 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
213 K 15 K 44.4 K

References

  1. Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer Revenue Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
238 M - 2.43 % $ 254 M germanyGermany
Processa Pharmaceuticals Processa Pharmaceuticals
PCSA
5 K $ 2.3 -1.29 % $ 3.01 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
9.59 M - 5.93 % $ 314 M canadaCanada
Albireo Pharma Albireo Pharma
ALBO
40.6 M - -0.23 % $ 916 M usaUSA
I-Mab I-Mab
IMAB
88 M - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
6.07 B - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
70.9 M - 2.54 % $ 160 B franceFrance
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
720 M $ 220.9 2.49 % $ 5 B danmarkDanmark
Aptinyx Aptinyx
APTX
1 M - -39.0 % $ 4.57 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
381 K - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
12.1 K - -1.52 % $ 24.7 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
720 M $ 19.57 1.77 % $ 915 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
325 K - - $ 26.5 M usaUSA
Phathom Pharmaceuticals Phathom Pharmaceuticals
PHAT
175 M $ 10.47 4.08 % $ 763 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
692 K - - $ 7.46 M israelIsrael
AgeX Therapeutics AgeX Therapeutics
AGE
142 K - -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
118 M - -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
100 M - 4.01 % $ 150 M canadaCanada
BeiGene, Ltd. BeiGene, Ltd.
BGNE
5.34 B - 0.49 % $ 251 B cayman-islandsCayman-islands
bluebird bio bluebird bio
BLUE
29.5 M - - $ 546 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
1.08 B - - - russiaRussia
Cara Therapeutics Cara Therapeutics
CARA
21 M - -3.03 % $ 260 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
1 M - - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
1.26 M - 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
13 K - -9.65 % $ 45.9 M usaUSA
Pliant Therapeutics Pliant Therapeutics
PLRX
1.58 M $ 1.31 2.34 % $ 80.4 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
242 K $ 1.33 0.76 % $ 339 M britainBritain
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
882 K $ 8.31 1.59 % $ 111 M usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
3.51 M $ 47.09 1.42 % $ 4.23 B schweizSchweiz
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
43 K - -5.98 % $ 34.1 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
32.2 M - - $ 3.74 B usaUSA
Prelude Therapeutics Incorporated Prelude Therapeutics Incorporated
PRLD
12.1 M $ 3.26 4.49 % $ 251 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
277 M - - $ 2.02 B usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
167 M - -4.8 % $ 255 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
42.8 K - - $ 40.5 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
886 K - - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
48.9 M - - $ 867 M germanyGermany
Palatin Technologies Palatin Technologies
PTN
4.49 M $ 21.0 5.79 % $ 19.5 M usaUSA
Pulmatrix Pulmatrix
PULM
7.81 M $ 2.12 -1.4 % $ 7.74 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
14.1 M $ 4.53 5.1 % $ 868 M canadaCanada
Homology Medicines Homology Medicines
FIXX
53.7 M - 0.77 % $ 53.4 M usaUSA